

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

AQUACELL TECHNOLOGIES INC
Form 10QSB
May 15, 2003

U. S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Form 10-QSB

(Mark one)

Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2003.

Transition report under Section 13 or 15(d) of the Exchange Act
For the transition period from _____ to _____

Commission file number 1-16165

AQUACELL TECHNOLOGIES, INC.
(Exact Name of Small Business Issuers as Specified in its Charter)

Delaware 33-0750453
(State of Incorporation) (IRS employer identification number)

10410 Trademark Street
Rancho Cucamonga, CA 91730
(Address of Principal Executive Offices)

(909) 987-0456
(Issuer's Telephone Number, Including Area Code)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDING DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of Securities under a plan confirmed by a court.

Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

Common Stock, \$.001 par value 8,726,224 shares outstanding
as of May 12, 2003

Transitional Small Business Disclosure Format (check one):

Yes No

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

AQUACELL TECHNOLOGIES, INC.

FORM 10-QSB

FOR THE QUARTER ENDED MARCH 31, 2003

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

	PAGE
Item 1 Financial Statements:	
Condensed Consolidated Balance Sheet as of March 31, 2003	1
Condensed Consolidated Statements of Operations for the three and nine month periods ended March 31, 2003 and 2002	2
Condensed Consolidated Statements of Cash Flow for the nine month periods ended March 31, 2003 and 2002	3
Notes to Condensed Consolidated Financial Statements	5
Item 2 Management's Discussion and Analysis:	8
Forward-Looking Statements Overview Results of Operations Liquidity and Capital Resources	
Item 3 Controls and Procedures	10

PART II - OTHER INFORMATION

Item 4 Submission of Matters to a Vote of Security Holders	10
Item 6 Exhibits and reports on Form 8-K	10
Signature	10
Certifications	11

i

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

March 31, 2003

(Unaudited)

ASSETS

Current assets:

Cash	\$ 101,000
Receivable from sale of preferred stock	95,000
Notes receivable, including accrued interest of \$69,000	210,000
Accounts receivable, net of allowance of \$4,000	300,000
Inventories	98,000
Prepaid expenses and other current assets	116,000

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

Total current assets	920,000
Property and equipment, net	45,000
Other assets:	
Goodwill	1,114,000
Investments	274,000
Patents, net	104,000
Security deposits	14,000
Total other assets	1,506,000
	\$2,471,000
LIABILITIES	
Current liabilities:	
Accounts payable	\$ 736,000
Accrued expenses	393,000
Loans payable to finance company	177,000
Loan payable	100,000
Customer deposits	29,000
Current portion of long-term debt.....	4,000
Loans payable to related parties.....	79,000
Total current liabilities	1,518,000
Long-term debt, net of current portion.....	4,000
Total liabilities	1,522,000
Commitments and contingencies	
STOCKHOLDERS' EQUITY:	
Preferred stock, par value \$.001; 8,130,000 shares authorized; none issued and outstanding	-
Preferred stock Series A convertible; par value \$.001; 1,870,000 shares authorized; 685,000 shares issued and outstanding	1,000
Common stock, par value \$.001; 40,000,000 shares authorized; 8,701,224 shares issued and outstanding	9,000
Additional paid-in capital	13,313,000
Accumulated deficit	(11,881,000)
	1,442,000
Unamortized deferred compensation	(493,000)
Total stockholders' equity	949,000
	\$ 2,471,000

See notes to condensed consolidated financial statements

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2003	2002	2003	2002
Revenue:				
Net sales	\$ 188,000	\$ 208,000	\$ 1,322,000	\$ 360,000
Rental income	1,000	2,000	5,000	6,000
	189,000	210,000	1,327,000	366,000
Cost of sales	139,000	103,000	743,000	166,000
	50,000	107,000	584,000	200,000
Selling, general and administrative expenses:				
Salaries and wages	329,000	253,000	922,000	720,000
Legal, accounting and other professional expenses	36,000	72,000	140,000	339,000
Stock based compensation	56,000	137,000	156,000	587,000
Impairment loss on investment in Corbett Water Technologies, Inc	-	-	-	1,226,000
Other	257,000	203,000	779,000	720,000
Recovery of notes receivable reserve	(57,000)	-	(57,000)	-
	621,000	665,000	1,940,000	3,592,000
Loss from operations before other (expense) income ..	(571,000)	(558,000)	(1,356,000)	(3,392,000)
Other (expense) income:				
Amortization of loan fee	(58,000)	-	(58,000)	-
Interest expense	(14,000)	-	(36,000)	-
Interest income	13,000	30,000	45,000	105,000
Other income	-	-	-	100,000
	(59,000)	30,000	(49,000)	205,000
Net loss attributable to common stockholders	\$ (630,000)	\$ (528,000)	\$ (1,405,000)	\$ (3,187,000)
Weighted average shares outstanding- basic and diluted				
	8,692,000	8,240,000	8,631,000	8,032,000
Net loss per common share- basic and diluted				
	\$ (0.07)	\$ (0.06)	\$ (0.16)	\$ (0.40)

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

See notes to condensed consolidated financial statements

2

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (Unaudited)

	Nine Months Ended March 31,	
	2003	2002
Cash flows from operating activities:		
Net loss	\$(1,405,000)	\$(3,187,000)
Adjustment to reconcile net loss to net cash used in operating activities:		
Impairment loss on investment in Corbett Water Technologies, Inc.	-	1,226,000
Stock based compensation	156,000	587,000
Amortization of loan fee.....	58,000	-
Depreciation and amortization	46,000	41,000
Reduction of reserve on notes receivable.....	(57,000)	-
Changes in:		
Accounts receivable	(109,000)	(2,000)
Accrued interest receivable	(44,000)	18,000
Prepaid expenses and other current assets	100,000	30,000
Inventories	4,000	(19,000)
Accounts payable	18,000	304,000
Accrued expenses	631,000	270,000
Customer deposits	13,000	32,000
Other	5,000	-
Net cash used in operating activities ...	(584,000)	(700,000)
Cash flows from investing activities:		
Notes issued for purchased of property and equipment, net of payments	8,000	-
Collections on notes receivable	-	513,000
Purchase of property and equipment	(12,000)	(4,000)
Net cash provided by (used in) investing activities	(4,000)	509,000
Cash flows from financing activities:		
Proceeds from private placement of preferred stock	311,000	-
Loan from unrelated third party	100,000	-
Proceeds from loans from finance company	438,000	-
Payments on loans from finance company	(261,000)	-
Loans and advances from related parties, net ..	50,000	(4,000)

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

Net cash provided by (used in) financing activities	638,000	(4,000)
Increase (decrease) in cash	\$ 50,000	\$ (195,000)
Cash, beginning of period	51,000	298,000
Cash, end of period	\$ 101,000	\$ 103,000

See notes to condensed consolidated financial statements

3

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Continued)

	Nine Months Ended March 31,	
	2003	2002
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 20,000	\$ -
Supplemental schedule of non-cash investing and financing activities:		
Issuance of preferred stock in private placement for expenses of the offering	\$ 25,000	\$ -
Note payments of principal and interest made by management with their shares of the Company's common stock	\$ -	\$ 251,000
Issuance of common stock as loan fee	\$ 62,000	\$ -
Issuance of common stock in connection with investment	\$ -	\$ 1,500,000
Issuance of common stock and warrants for services to the company	\$ 55,000	\$ 525,000
Retirement of 82,422 shares of treasury stock....	\$ 251,000	\$ -
Principal payments on notes receivable by conversion of accrued officers' salaries.....	\$ 437,000	\$ 218,000
Issuance of common stock to acquire subsidiary ..	\$ -	\$ 1,000,000
Issuance of common stock to satisfy indebtedness of acquired subsidiary's vendors	\$ -	\$ 189,000
Receivable on preferred stock.....	\$ 95,000	\$ -

See notes to condensed consolidated financial statements

4

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

March 31, 2003 (Unaudited)

NOTE A - BASIS OF PRESENTATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with instructions to Form 10-QSB. Accordingly, they do not include all of the information and footnotes required by U. S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the nine months ended March 31, 2003 are not necessarily indicative of the results to be expected for the full year. For further information, refer to the Company's annual report filed on Form 10-KSB for the year ended June 30, 2002.

NOTE B - RECEIVABLE FROM SALE OF PREFERRED STOCK

At March 31, 2003, the receivable from sale of preferred stock represented the amount owed for the sale of shares of Series A convertible preferred stock in the private placement (see Note J). The investor's payment was received on April 9, 2003.

NOTE C - NOTES RECEIVABLE

At March 31, 2003, the notes receivable consist of \$50,000 from a non-affiliated party and \$399,000 from non-director/employee stockholders and entities owned by them at an annual interest rate of 8%. Notes totaling \$1,750,000 maturing August 16, 2001 were extended to September 16, 2001. At September 16, 2001 the notes were restructured into twelve-month installment notes collateralized by marketable securities with the first installment due October 16, 2001. Officers/stockholders of Aquacell, have personally guaranteed up to \$1,750,000 of the notes and have offered as collateral designated assets and have paid \$1,005,000 in principal and \$32,000 in interest through contribution of salaries in the amount of \$786,000 and surrender of 82,422 shares of the Company's common stock, valued at \$251,000, on a cumulative basis through March 31, 2003. Such shares were recorded as treasury stock and retired by the Company at December 31, 2002. During March 2003 the officers/stockholders contributed accrued salaries totaling \$153,000 as payment under the guaranty provisions of the notes receivable. The Company recorded an adjustment to reflect a reduction in the estimated fair value of these notes of \$365,000 at June 30, 2001. At March 31, 2003 the adjustment was decreased by \$57,000 to equal the remaining principal balances of the notes. Such recovery has been reported in the Statement of Operations. The balance of the notes are unsecured and matured between March 2002 and October 2002. The note that matured in October 2002 was extended for one year. Interest receivable at March 31, 2003 amounted to \$8,000 from a non-affiliated party and \$61,000 from non-director/employee stockholders and entities owned by them.

NOTE D - INVENTORIES

Inventories consist of the following at March 31, 2003:

Raw materials	\$ 76,000
Work in progress	22,000

	\$ 98,000

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2003 (Unaudited)

NOTE E - PROPERTY AND EQUIPMENT

Property and equipment is summarized as follows at March 31, 2003:

Furniture and fixtures	\$	35,000
Equipment - office		95,000
Machinery and equipment		122,000
Rental units		9,000
Leasehold improvements		10,000
Truck		11,000

		282,000
Less accumulated depreciation		237,000

	\$	45,000

NOTE F - LOANS PAYABLE TO FINANCE COMPANY

On August 24, 2002 the Company entered into a credit facility agreement to finance the receivables of its largest customer, Corbett Water Technologies, Inc. The agreement is for a one-year term, and calls for interest at the rate 18 1/4% per annum in addition to the payment of certain processing fees. Payments are made directly to the lender by Corbett Water and the financing is collateralized by the Company's accounts receivable from Corbett Water Technologies, Inc. (See Note J)

NOTE G - LOAN PAYABLE

On January 6, 2003 the Company borrowed \$100,000 from an unrelated party for a period of three months. Terms of the loan call for interest at the rate of 18% per annum and the payment of 100,000 shares of the Company's common stock valued at \$62,000. For the nine months ended March 31, 2003 amortization of this loan fee amounted to \$58,000. On April 6, 2003 the Company repaid \$50,000 of the loan, together with all interest due to that date and extended the remaining \$50,000 principal for an additional thirty day period at the same rate of interest. The Company issued an additional 25,000 shares of its common stock as consideration for the extension.

NOTE H - LOANS PAYABLE TO RELATED PARTIES

At March 31, 2003 the loans payable to related parties consist of unsecured demand interest free loans of \$79,000.

NOTE I - LONG TERM DEBT

At March 31, 2003 long-term debt consists of an installment note, secured by a truck, payable in monthly payments of \$342 through February 2005. Maturities on the note follows:

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

Twelve months ending March 31, 2004	\$ 4,000
March 31, 2005	4,000

	\$ 8,000

6

AQUACELL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2003 (Unaudited)

NOTE J - EQUITY TRANSACTIONS

In connection with a one-year credit facility agreement entered into in August 2002, the lender was granted warrants to purchase 160,000 shares of common stock, at an exercise price of \$0.78 per share, whose total value is estimated at approximately \$43,000. The estimated value of the warrants is being amortized to expense over one year. Amortization for the nine months ended March 31, 2003 was \$32,000.

On December 4, 2002 stockholders approved the adoption of the Company's 2002 Directors Stock Option Plan. The plan covers an aggregate of 500,000 shares of the Company's common stock for non-employee directors.

In connection with a one-year consulting agreement entered into in March 2003, the Company issued 150,000 warrants to purchase common stock of the Company at an exercise price of \$1.00 per share, whose total value is estimated at approximately \$12,000. The estimated value of the warrants is being amortized to expense over one year. Amortization for the nine months ended March 31, 2003 was \$1,000.

During March 2003 the Company completed a private placement of 685,000 shares of a newly designated Series A Convertible Preferred Stock. The offering consists of one share of preferred stock at a price of \$0.63 per share and one Class A common stock purchase warrant exercisable at \$1.16 per share. The Series A Convertible Preferred Stock carries an 8% dividend and is convertible into the Company's common stock on a one for one basis. The Series A Convertible Preferred carries a mandatory conversion feature. In connection with this offering the Company received gross proceeds of \$311,000 exclusive of \$95,000 received in April 2003. As part of this offering 40,000 shares were issued to the Company's attorney as consideration for expenses of the offering.

NOTE K - SUBSEQUENT EVENT

Subsequent to March 31, 2003 the Company raised net proceeds of approximately \$329,000 through the sale of 500,000 shares of Series A Convertible Preferred Stock at \$0.75 per share and 500,000 Class A Common Stock Purchase Warrants exercisable at \$1.60 per share.

7

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

Forward-Looking Statements

When used in this Form 10-QSB and in future filings by the Company with the Commission, statements identified by the words "believe", "positioned", "estimate", "project", "target", "continue", "will", "intend", "expect", "future", "anticipates", and similar expressions express management's present belief, expectations or intentions regarding the Company's future performance within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The Company has no obligations to publicly release the result of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

Overview

The following discussions and analysis should be read in conjunction with the Company's condensed consolidated financial statements and the notes presented following the condensed consolidated financial statements. The discussion of results, causes and trends should not be construed to imply any conclusion that such results or trends will necessarily continue in the future.

For the nine-months ended March 31, 2003 we increased revenues by 263% to \$1,327,000 while cutting our per share losses by 60% and decreasing our selling, general and administrative expenses by 46% to \$1,940,000. This increase in revenues is primarily attributable to the growing acceptance of our flagship Purific Water Cooler in the marketplace.

Revenues for the quarter ended March 31, 2003 fell short of the Company's target and expectations as a result of the Company's restructuring of its exclusive working relationship with Corbett Water Technologies, Inc. We are restructuring our exclusive relationship with Corbett to allow us to implement a national marketing program. The Company will be setting up various channels of distribution and each of these selling groups will be responsible for payment of their own expenses. As a result, the Company does not anticipate incurring significant marketing costs as a result of the above arrangements.

We recently completed, through our AquaCell Media subsidiary, a successful product test of our Purificr Water Cooler as the first phase of a project funded by a Fortune 100 company and conducted by a consultant group they hired for its implementation. Given these favorable results, we are collectively proceeding to the next phase for the funding of the market test, in order to find the most effective means for marketing the Purificr cooler to the residential community, the fastest growing segment of the bottled water industry.

Results of Operations

During the nine months ended March 31, 2003 on a consolidated basis, we increased revenues by 263% to \$1,327,000 as compared to \$366,000 for the similar period of the preceding year. This increase is primarily attributable to an increase in sales to Corbett Water in the amount of approximately \$303,000, sales to Connecticut Water of approximately \$48,000, and a sales increase by our Water Science Technologies (WST) subsidiary in the approximate amount of \$405,000. Net loss on a consolidated basis for the nine months ended March 31, 2003 was decreased by 56% to \$1,405,000 or \$0.16 per share, as compared to \$3,187,000 or \$0.40 per share for the same period of the prior year. The decrease in the loss is primarily attributable to the increase in revenues, as well as a reduction in selling, general and administrative expenses of

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

\$1,652,000 or 46%. The significant decrease in the selling, general and administrative expenses was principally a result of a \$1,226,000 impairment charge impacting only the prior period.

8

On a consolidated basis gross margin percentage decreased to 44% for the nine months ended March 31, 2003 as compared to 56% for the prior period. This decrease is attributable to the 25% gross margin maintained by our WST subsidiary. Our Global Water-Aquacell subsidiary continued to reflect a gross margin of approximately 55%.

Salaries and wages increased by \$202,000 for the nine months ended March 31, 2003 over the comparable prior year period. This increase is primarily attributable to salaries incurred by our WST subsidiary of approximately \$145,000 and payments to senior management in the approximate amount of \$75,000. Legal, accounting and other professional expenses decreased by approximately \$199,000 for the nine months ended March 31, 2003 primarily attributable to terminated consulting agreements. Stock based compensation decreased by \$431,000 to \$156,000 for the nine months ended March 31, 2003. Other selling, general and administrative expenses, consisting primarily of rent-\$120,000, telephone and utilities- \$58,000, travel- \$45,000, business promotion- \$117,000, insurance- \$70,000 and vehicle expenses- \$70,000, increased by approximately \$59,000 to \$779,000 for the nine months ended March 31, 2003.

Liquidity and Capital Resources

During the nine months ended March 31, 2003 we financed our operations primarily from the collections of receivables in the normal course of business; the financing of certain receivables due from Corbett Water Technologies and the sale of equity securities. During March 2003 the Company received gross proceeds of \$311,000 from the sale of its preferred stock and an additional \$95,000 in April 2003. A net increase in loans from officers and others amounted to \$50,000 during the period. The Company borrowed \$100,000 from an unrelated party.

Cash used by operations during the nine months ended March 31, 2003 amounted to \$584,000. Net loss of \$1,405,000 was reduced by a non-cash stock based compensation and loan fee amortization in the amount of \$214,000, depreciation and amortization of \$46,000 and increased by a reduction in notes receivable reserve of \$57,000. Cash used by operations was further increased by an increase in accounts receivable in the amount of \$109,000 and decreased by accounts payable and accrued expenses in the amount of \$649,000. Net loss was further decreased by net changes in accrued interest receivable, prepaid expenses, customer deposits, inventories and other amounting to \$78,000.

Cash used in investing activities during nine months ended March 31, 2003 represented expenditures for property and equipment in the amount of \$12,000 decreased by notes issued for the purchase of equipment in the amount of \$8,000, net of repayments.

Cash provided by financing activities was approximately \$638,000. The Company borrowed \$100,000 from an unrelated party and \$50,000 from related parties. Sales of equity securities amounted to \$311,000 and net proceeds from accounts receivable financing amounted to \$177,000.

Subsequent to March 31, 2003 the Company raised net proceeds of \$329,000 from the sale of equity securities.

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

We have granted warrants, subsequent to our initial public offering in connection with consulting, marketing and financing agreements and the sale of equity securities that may generate additional capital of up to approximately \$6,200,000 if exercised. There is no assurance however, that any of the warrants will be exercised.

The principal payments of \$153,000, which consisted of contributed accrued officers' salaries, reduced the balance on the \$1,750,000 installment notes receivable to \$307,000 at March 31, 2003.

Management believes that the collections on notes receivable, cash flows expected to be generated from future operations and anticipated additional equity financings will be sufficient to meet presently anticipated needs for working capital and capital expenditures through at least the next 12 months; however, there can be no assurance in that regard. The Company presently has no material commitments for future capital expenditures.

9

ITEM 3. CONTROLS AND PROCEDURES

Within the 90 days prior to the date of this Report the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's chief executive officer and chief financial officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Rule 13a-14 adopted under the Securities Exchange Act of 1934. Based upon that evaluation, the chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures are effective. There were no significant changes in the Company's internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation.

PART II. OTHER INFORMATION

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

NONE

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

DURING THE PERIOD COVERED BY THIS REPORT ON FORM 10-QSB THERE WERE NO REPORTS FILED ON FORM 8-K.

SIGNATURE

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AquaCell Technologies, Inc.

Registrant

Date: May 15, 2003

/s/ Gary S. Wolff

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

Gary S. Wolff
Chief Financial Officer

10

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AquaCell Technologies, Inc. (the "Company") on Form 10-QSB for the third fiscal quarter ended March 31, 2003 as filed with the Securities and Exchange Commission (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: May 15, 2003

/s/ James C. Witham

Name: James C. Witham
Title: Chief Executive Officer

Dated: May 15, 2003

/s/ Gary S. Wolff

Name: Gary S. Wolff
Title: Chief Financial Officer

11

CERTIFICATION PURSUANT TO RULE 13a-14 AND 15d-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, James C. Witham, Chief Executive Officer of AquaCell Technologies, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-QSB of AquaCell Technologies, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - (a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - (b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days of the filing date of this quarterly report (the "Evaluation Date"); and
 - (c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
 - (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Dated: May 15, 2003

/s/ James C. Witham

Name: James C. Witham

Title: Chief Executive Officer

12

CERTIFICATION PURSUANT TO RULE 13a-14 AND 15d-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Gary S. Wolff, Chief Financial Officer of AquaCell Technologies, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-QSB of AquaCell Technologies, Inc.;

Edgar Filing: AQUACELL TECHNOLOGIES INC - Form 10QSB

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - (a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - (b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days of the filing date of this quarterly report (the "Evaluation Date"); and
 - (c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
 - (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Dated: May 15, 2003

/s/ Gary S. Wolff

Name: Gary S. Wolff

Title: Chief Financial Officer